Author Index to Volume 29

ABDALLA, H.I. see Homburg, R. ADAMS, J. see Hague, W.M.

ADDISON, G.M. see Clayton, P.E.

ADLARD, P. see Buchanan, C.R.

AFSHAR, F. see Harris, P.E.

ALAGHBAND-ZADEH, J. see Eden, J.A.

AMIEL, S.A. see Holly, J.M.P.

ANDERSON, D.C. see Mavroudis, K.

ANG, V.T.Y. see Nussey, S.S.

ARENDT, J. Melatonin, 205

Arntzenius, A.B., Elte, J.W.F., Frolich, M. & HAAK, A. The significance of the initial FT4-index for the management of single daily dose methimazole treatment of hyperthyroidism, 239

ASHBY, J.P., LOVERIDGE, N., BROWN, R.C., ZANELLI, J.M., RINSLER, M.G. & WATTS, R.W.E. Anomalies in the assay of parathyroid hormone in normocalcaemic patients with renal stone disease, 131

ASTON, J.P., BROWN, R.C., CURLEY, I., WHEELER, M.H. & WOODHEAD, J.S. Secretion of intact PTH by dispersed human hyperparathyroid cells, 643 AURBACH-KLIPPER, Y. see Laron, Z.

Balks, H.J., Conlon, J.M., Creutzfeldt, W. & Stöckmann, F. Circulating bradykinin-like immunoreactivity and the pentagastrin-induced carcinoid flush. 141

BARRECA, A. see Ferrari, C.

BAYLIS, P.H. & THOMPSON, C.J. Osmoregulation of vasopressin secretion and thirst in health and disease, 549

BECKETT, G.J. see Gow, S.M.

BELL, J. see Dandona, P.

BERGH, T. see Rasmussen, C.

BERTAGNA, X. see Raux Demay, M.C.

Besser, G.M. see Grossman, A.B.

BESSER, G.M. see Harris, P.E.

BEYZAVI, K. see Hampton, S.M.

BIDDLECOMBE, R.A. see Holly, J.M.P.

Blunt, S., Woods, C.A., Joplin, G.F. & Burrin, J.M. The role of a highly sensitive amplified enzyme immunoassay for thyrotrophin in the evaluation of thyrotroph function in hypopituitary patients, 387

BOGHEN, M. see Ferrari, C.

Boscaro, M. see Sonino, N.

BROOK, C.G.D. Treatment of growth deficiency, 197

BROOK, C.G.D. see Hindmarsh, P.C.

Brown, R.C. see Ashby, J.P.

Brown, R.C. see Aston, J.P.

BROWNELL, J. see Rasmussen, C.

BUCHANAN, C.R., STANHOPE, R., ADLARD, P., JONES, J., GRANT, D.B. & PREECE, M.A. Gonadotrophin, growth hormone and prolactin secretion in children with primary hypothyroidism, 427

BURGER, H.G. see McLachlan, R.I.

BURGER, H.G. see Tsatsoulis, A.

BURRIN, J.M. see Blunt, S.

BURT, D. see Davis, J.R.E.

CAIDAHL, K. see Nystrom, E.

CALDWELL, G. see Gow, S.M. CAPELLI, M. see Paradisi, R.

CARRANZA-LIRA, S. see Ulloa-Aguirre, A.

CARTER, G.D. see Eden, J.A.

CASOLI, P. see Valcavi, R.

CASSORLA, F. see Rose, R.K.

CHANG, C.C. see Chang, T.C.

CHANG, T.C., KUO, S.H., LIAW, K.Y., CHANG, C.C. & CHEN, F.W. Cell kinetics, DNA content and TSH receptor-adenylate cyclase system in differentiated thyroid cancer, 477

CHARD, T. see Holly, J.M.P.

CHARD, T. see Harris, P.E.

CHAUDRY, L. see Harris, P.E.

CHEN, F.W. see Chang, T.C.

CLARK, J.D.A., RAGGATT, P.R. & EDWARDS, O.M. Hypothalamic hypogonadism following major head injury, 153

CLAYTON, P.E., SHALET, S.M., PRICE, D.A. & ADDISON, G.M. Growth hormone responses to oxandrolone in boys with constitutional delay of growth and puberty (CDGP), 123

COATES, P.J., McNicol., A., Doniach, I. & Rees, L.H. Increased production of α-melanocytestimulating hormone in the pituitary gland of patients with untreated Addison's disease, 421

COATES, P. see Harris, P.E.

CONLON, J.M. see Balks, H.J.

COOKE, B.A. see Harris, P.E.

CORRIE, J.E.T. see Davis, J.R.E.

COUMAR, A. see Dandona, P.

Coy, D.H. see Grossman, A.B.

CREUTZFELDT, W. see Balks, H.J. CURLEY, I. see Aston, J.P.

DALY, J.G. see LAW, A.

DANDONA, P., COUMAR, A., GILL, D.S., BELL, J. &

THOMAS, M. Sodium fluoride stimulates osteocalcin in normal subjects, 437

DAVIS, J.R.E., BURT, D., CORRIE, J.E.T., EDWARDS, C.R.W. & SHEPPARD, M.C. Dexamethasone-suppressible hyperaldosternoism: studies on overproduction of 18-hydroxycortisol in three affected family members, 297

DE KEYZER, Y. see Raux DEMAY, M.C.

DE KRETSER, D.M. see Tsatsoulis, A.

DE KRETSER, D.M. see Mclachlan, R.I.

DESAI, R.K., NORMAN, R.J., JIALAL, I. & JOUBERT, S.M. Spectrum of thyroid function abnormalities in gestational trophoblastic neoplasia, 583

DICKERMAN, Z. see Laron, Z.

DIEGUEZ, C. see Valcavi, R. Dogs, M. see Pirke, K.M.

DONIACH, I. see Coates, P.J.

DUBIN, A. see Ferrari, C.

Dunger, D.B. see Holly, J.M.P.

EDEN, J.A., JONES, J., CARTER, G.D. & ALAGHBAND-ZADEH, J. A comparison of follicular fluid levels of insulin-like growth factor-1 in normal dominant and cohort follicles, polycystic and multicystic ovaries, 327

EDGE, J.A. see Holly, J.M.P.

EDWARDS, C.R.W. see Davis, J.R.E.

EDWARDS, O.M. see Clark, J.D.A.

ELTE, J.W.F. see Arntzenius, A.B.

ENDO, K. see Kasagi, K.

ESHEL, A. see Homburg, R.

EVANS, A. see Mavroudis, K.

Evans, R. see Matta, W.H.

FABBRI, R. see Paradisi, R. FAGER, G. see Nystrom, E.

FAURE, N. & LEMAY, A. Acute pituitary-ovarian response during chronic luteinizing hormonereleasing hormone agonist administration in polycystic ovarian syndrome, 403

FAVA, G.A. see Sonino, N.

Ferrari, C., Paracchi, A., Romano, C., Gerevini, G., Boghen, M., Barreca A., Fortini, P. & Dubin, A. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients, 467

FICHTER, M.M. see Pirke, K.M.

FLAMIGNI, C. see Paradisi, R.

FLASTERSTEIN, B. see Laron, Z.

FLETCHER, J., FRANKLYN J.A., McLachlan, S.M., YOUNG, E. & SHEPPARD, M.C. HLA class II DNA genotypes in Graves' disease: clues to the inheritance of the HLA-linked component of susceptibility, 539

FORTINI, P. see Ferrari, C.

FRANKLYN, J.A. & SHEPPARD, M.C. Hormonal control of gene expression, 337

FRANKLYN, J.A. see Fletcher, J.

FRANKS, S. see Scanlon, M.J.

FRÖLICH, M. see Arntzenius, A.B.

FRÖLICH, M. see Looij, B.J.

FUJISHIMA, M. see Sato, K.

FUKUDA, S. see Ishikawa, S.-E.

GARZA-FLORES, J. see Ulloa-Aguirre, A.

GEREVINI, G. see Ferrari, C.

GILL, D.S. see Dandona, P.

GIRARD, F. see Raux Demay, M.C.

GONZALEZ-CASTILLO, A. see Ulloa-Aguirre, A.

GOOREN, L.J.G. see Spijkstra, I.J.

GORDON, P.A.L. see Treasure, J.L.

GOW, M., CALDWELL, G., TOFT, A.D., SWEETING, V.M. & BECKETT, G.J. Restoration of normal thyrotrophin secretion reduces the abnormally high serum glutathione S-transferase levels found in patients receiving thyroxine replacement therapy, 249

GRANDI, S. see Sonino, N.

GRANT, D.B. see Buchanan, C.R.

GROSSI, C. see Paradisi, R.

GROSSMAN, A.B., HOWLETT, T.A., PERRY. L., COY, D.H., SAVAGE, M.O., LAVENDER, P., REES, L.H. & BESSER, G.M. CRF in the differential diagnosis of the Cushing's syndrome: a comparison with the dexamethasone suppression test, 167

HAAK, A. see ARNTZENIUS, A.B.

HAGUE, W.M., ADAMS, J., REEDERS, S.T., PETO, T.E.A. & JACOBS, H.S. Familial polycystic ovaries: a genetic disease, 593

HAGUE, W.M. see Law, A.

HAMPTON, S.M., BEYZAVI, K., TEALE, D. & MARKS, V. A direct assay for proinsulin and its applications in hypoglycaemia, 9

HANAFUSA, T. see Yamada, Y.

HARRIS, P.E., PERRY, L., CHARD, T., CHAUDRY, L., COOKE, B.A., TOUZEL, R., COATES, P., LOWE, D.G., AFSHAR, F., WASS, J.A.H. & BESSER, G.M. Immunoreactive human chorionic gonadotrophin from the cyst fluid and CSF of patients with craniopharyngioma, 503

HATABU, H. see KASAGI, K. HEDING, L.G. see Laron, Z.

HESP, R. see Matta, W.H.

HIMSWORTH, R.L. see Law, A.

HINDMARSH, P.C., MATTHEWS, D.R. & BROOK, C.G.D. Growth hormone secretion in children determined by time series analysis, 35

HINDMARSH, P.C., PRINGLE, P.J. & BROOK, C.G.D. Cholinergic muscarinic blockade produces shortterm suppression of growth hormone secretion in children with tall stature, 289

- HOLLY, J.M.P., BIDDLECOMBE, R.A., DUNGER, D.B., EDGE, J.A., AMIEL, S.A., HOWELL, R., CHARD, T., REES, L.H. & WASS, J.A.H. Circadian variation of GH-dependent IGF-binding protein in diabetes mellitus and its relationship to insulin. A new role for insulin?, 667
- HOMBURG, R., ESHEL, A., ABDALA, H.I. & JACOBS, H.S. Growth hormone facilitates ovulation induction by gonadotrophins, 113
- HONOUR, J.W. see Law, A. HOWELL, R. see Holly, J.M.P.
- HOWLETT, T.A. see Grossman, A.B. HUHTANIEMI, I. see Ranta, T.
- IIDA, Y. see Kasagi, K. IIZUKA, R. see Nakamura, Y. IKENOUE, H. see Sato, K.
- INABA, K., UMEDA, Y., YAMANE, Y., URAKAMI, M. & INADA, M. Characterization of human platelet vasopressin receptor and the relation between vasopressin-induced platelet aggregation and vasopressin binding to platelets, 377
- INADA, M. see Inaba, K.
- ISHIKAWA, S.-E., SAITO, T., KANEKO, K., OKADA, K., FUKUDA, S. & KUZUYA, T. Hypermineralocorticism without elevation of plasma aldosterone: deoxycorticosterone-producing adrenal adenoma and hyperplasia, 367
- Ітон, H. see Yamada, Y.
- JACOBS, H.S. see Hague, W.M.
- JACOBS, H.S. see Homburg, R.
- JAMES, V.H.T. see Scanlon, M.J.
- JEFFCOATE, S.L. see LAW, A.
- JENKINS, J.S. see Nussey, S.S.
- JENKINS, J.S. see Prysor-Jones, R.A.
- JENNINGS, P.E. see O'Malley, B.P.
- JIALAL, I. see Desai, R.K.
- JONES, J. see Buchanan, C.R.
- JONES, J. see Eden, J.A.
- JOPLIN, G.F. see Blunt, S.
- JOPLIN, G.F. see Law, A.
- JOUBERT, S.M. see Desai, R.K.
- JUDD, S.J. see Steele, P.A.
- KANEKO, K. see Ishikawa, S.-E.
- KASAGI, K., HATABU, H., IIDA, Y., ENDO, K. & Konishi, J. Studies on thyrotropin receptor antibodies in patients with euthyroid Graves' disease,
- KAWACHI, M. see Yamada, Y.
- KING, E.A. see Treasure, J.L.
- KIYOKAWA, K. see Yamada, Y.
- KLIJN, J.G.M. see Lamberts, S.W.J.
- Konishi, J. see Kasagi, K.
- KONO, N. see Yamada, Y.
- KRUSEMAN, A.C.N. see Looij, B.J.

- Kuo, S.H. see Chang, T.C.
- KUZUYA, T. see Ishikawa, S.-E.
- LAMBERTS, S.W.J., UITTERLINDEN, P., SCHUUFF, P.C. & KLUN, J.G.M. Therapy of acromegaly with Sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure', 411
- LARON, Z., AURBACH-KLIPPER, Y., FLASTERSTEIN, B., LITWIN, A., DICKERMAN, Z. & HEDING, L.G. Changes in endogenous insulin secretion during childhood as expressed by plasma and urinary Cpeptide, 625
- LAVENDER, P. see Grossman, A.B.
- LAW, A., HAGUE, W.M., DALY, J.G., HONOUR, J.W., TAYLOR, N., JEFFCOATE, S.L., HIMSWORTH, R.L. & JOPLIN, G.F. Inappropriate ACTH concentrations in two patients with functioning adrenocortical carcinoma, 53
- LEMAY, A. see Faure, N.
- LIAW, K.Y. see Chang, T.C.
- LINDSTEDT, G. see Nystrom, E.
- LITWIN, A. see Laron, Z.
- LOOU, B.J., ROELFSEMA, F., VAN DER HEIDE, D., FRÖLICH, M., SOUVERUN, J.H.M. & KRUSEMAN, A.C.N. The effect of calcitonin on growth hormone secretion in man, 517
 - LOVERIDGE, N. see Ashby, J.P.
- LOWE, D.G. see Harris, P.E.
- LUNDBERG, P.-A. see Nystrom, E.
- LUTON, J.P. see Raux Demay, M.C.
- McLachlan, R.I., Robertson, D.M., de Kretser, D.M. & BURGER, H.G. Advances in the physiology of inhibin and inhibin-related peptides, 77
- McLachlan, S.M. see Fletcher, J.
- McNicol, A. see Coates, P.J.
- MAMTORA, H. see Mavroudis, K.
- MANTERO, F. see Sonino, N.
- MARKS, V. see Hampton, S.M.
- MATTA, W.H., SHAW, R.W., HESP, R. & EVANS, R. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue Buserelin in premenopausal women, 45
- MATTHEWS, D.R. see Hindmarsh, P.C.
- MAVROUDIS, K., EVANS, A., MAMTORA, H., ANDER-SON, D.C. & ROBERTSON, W.R. Bioactive LH in women with polycystic ovaries and the effect of gonadotrophin suppression, 633
- MENDEZ, J.P. see Ulloa-Aguirre, A.
- MESSINIS, I.E. & TEMPLETON, A. Blockage of the positive feedback effect of oestradiol during prolonged administration of clomiphene citrate to normal women, 509
- MINEO, I. see Yamada, Y.
- Morris, I.D. see Tsatsoulis, A.

- NAKAMURA, Y., YOSHIMURA, Y., TAMAOKA, Y., UBUKATA Y., YOSHIDA, K., YAMADA, H., IIZUKA, R. & SUZUKI, M. Treatment of polycystic ovarian disease by inducing ovulation with pulsatile subcutaneous administration of human menopausal gonadotrophin, 395
- NAMBA, M. see Yamada, Y.
- NIKULA, H. see Ranta, T.
- NORMAN, R.J. see Desai, R.K.
- NORTHOVER, B.J. see O'Malley, B.P.
- NUSSEY, S.S., PAGE, S.R., ANG, V.T.Y., JENKINS, J.S. & WHITE, A. The effect of oxytocin infusion on adenohypophyseal and adrenal cortical responses to insulin-induced hypoglycaemia, 257
- NYSTRÖM, E., CAIDAHL, K., FAGER, G., WIKKELSÖ, C., LUNDBERG, P.-A. & LINDSTEDT, G. A double-blind cross-over 12-month study of L-thyroxine treatment of women with 'subclinical' hypothyroidism, 63
- OAKEY, R.E. see Wilson, S.C.
- OKADA, K. see Ishikawa, S.-E.
- OKAMURA, K. see Sato, K.
- O'MALLEY, B.P., ROSENTHAL, F.D., NORTHOVER, B.J., JENNINGS, P.E. & WOODS, K.L. Higher than conventional doses of carbimazole in the treatment of thyrotoxicosis, 281
- PAGE, M.D. see Valcavi, R.
- PAGE, S.R. see Nussey, S.S.
- PARACCHI, see Ferrarri, C.
- Paradisi, R., Grossi, C., Venturoli, S., Capelli, M., Porcu, E., Fabbri, R., Pasquali, R. & Flamigni, C. Evidence for a hypothalamic alteration of catecholamine metabolism in polycystic ovary syndrome, 317
- PASQUALI, R. see Paradisi, R.
- PEREZ-PALACIOS, G. see Ulloa-Aguirre, A.
- PERRY, L. see Grossman, A.B.
- PERRY, L. see Harris, P.E.
- PETO, T.E.A. see Hague, W.M.
- PIRKE, K.M., DOGS, M., FICHTER, M.M. & TUSCHL, R.J. Gonadotrophins. oestradiol and progesterone during the menstrual cycle in bulimia nervosa, 265
- Porcu, E. see Paradisi, R.
- PORTIOLI, I. see Valcavi, R.
- PREECE, M.A. see Buchanan, C.R.
- PRICE, D.A. see Clayton, P.E.
- PRINGLE, P.J. see Hindmarsh, P.G.
- PROESCHEL, M.F. see Raux Demay, M.C.
- PRYSOR-JONES, R.A. & JENKINS, J.S. Vasoactive intestinal peptide and anterior pituitary function, 677
- RAGGART, P.R. see CLARK, J.D.A.
- RANTA, T., YLINEN, K., STENMAN, U.-H., NIKULA,

- H. & HUHTANIEMI, I. Biological and immunological activity of human chorionic gonadotrophin in maternal serum during early pregnancy, 495
- RASMUSSEN, C., BERGH, T., WIDE, L. & BROWNELL, J. Long-term treatment with a new non-ergot long-acting dopamine-agonist, CV205-502, in women with hyperprolactinaemia, 271
- RAUX DEMAY, M.C., PROESCHEL, M.F., DE KEYZER, Y., BERTAGNA, X. LUTON, J.P. & GIRARD, F. Characterization of human corticotrophinreleasing hormone and pro-opiomelanocortinrelated peptides in a thymic carcinoid tumour responsible for Cushing's, 649
- REED, M.J. see Scanlon, M.J.
- REEDERS, S.T. see Hague, W.M.
- REES, L.H. see Coates, P.J.
- REES, L.H. see Grossman, A.B.
- REES, L.H. see Holly, J.M.P.
- RINSLER, M.G. see Ashby, J.P.
- ROBERTSON, D.M. see McLachlan, R.I.
- ROBERTSON, W.R. see Mavroudis, K.
- ROBERTSON, W.R. see Tsatsoulis, A.
- ROELFSEMA, F. see Looij, B.J.
- ROMANO, C. see Ferrari, C.
- ROSE, S.R., CASSORLA, F. & SHERINS, R.J. Normal neonatal surge of gonadotrophins and sex steroids in infants of men with isolated hypogonadotrophic hypogonadism, 577
- ROSENTHAL, F.D. see O'Malley, B.P.
- RUSSELL, G.F.M. see Treasure, J.L.
- SAITO, T. see Ishikawa, S.-E.
- SATO, K., OKAMURA, K., IKENOUE, H., SHIROZU, A., YOSHINARI, M. & FUJISHIMA, M. TSH dependent elevation of serum thyroglobulin in reversible primary hypothyroidism, 231
- SAVAGE, M.O. see Grossman, A.B. SCANLON, M.F. see Valcavi, R.
- SCANLON, M.J., WHORWOOD, C.B., FRANKS, S., REED, M.J. & JAMES, V.H.T. Serum androstanediol glucuronide concentrations in normal and hirsute women and patients with thyroid dysfunction, 529
- SCHUUFF, P.C. see Lamberts, S.W.J.
- SCOTT, J.S. see Wilson, S.C.
- SHALET, S.M. see Clayton, P.E.
- SHALET, S.M. see Tsatsoulis, A.
- Shaw, R.W. see Matta, W.H.
- SHEPPARD, M.C. see Davis, J.R.E.
- SHEPPARD, M.C. see Fletcher, J.
- SHEPPARD, M.C. see Franklyn, J.A.
- SHERINS, R.J. see Rose, S.R.
- SHIROOZU, A. see Sato, K.
- SONINO, N., FAVA, G.A., GRANDI, S., MANTERO, F. & BOSCARO, M. Stressful life events in the pathogenesis of Cushing's syndrome, 617

- SOUVERIJN, J.H.M. see Looij, B.J.
- SPIJKSTRA, I.J., SPINDER, T., GOOREN, L.J.G. & VAN KESSEL, H. Effects of opiate receptor blockade on gonadotrophin secretion before and after administration of the oestrogen receptor blocker tamoxifen in eugonadal men, 179
- SPINDER, T. see Spijkstra, I.J.
- STANHOPE, R. see Buchanan, C.R.
- STEELE, P.A. & JUDD, S.J. Positive and negative feed-back of progesterone on luteinizing hormone secretion in post-menopausal women, I
- STENMAN, U.-H. see Ranta, T.
- STÖCKMANN, F. see Balks, H.J.
- SUZUKI, M. see Nakamura, Y.
- SWEETING, V.M. see Gow, S.M.
- TAMAOKA, Y. see Nakamura, Y.
- TARUI, S. see Yamada, Y.
- TAYLOR, N. see Law, A.
- TEALE, D. see Hampton, S.M.
- TEMPLETON, A. see Messinis, I.E.
- THOMAS, M. see Dandona, P.
- THOMPSON, C.J. see Baylis, P.H.
- TOFT, A.D. see Gow, S.M.
- TOKUDA, Y. see Kasagi, K. TOUZEL, R. see Harris, P.E.
- TREASURE, J.L., WHEELER, W., KING, E.A., GOR-DON, P.A.L. & RUSSELL, G.F.M. Weight gain and reproductive function: ultrasonographic and endocrine features in anorexia nervosa, 607
- TSATSOULIS, A. SHALFT, S.M. & ROBERTSON, W.R. Changes in the qualitative and quantitative secretion of luteinizing hormone (LH) following orchidectomy in man, 189
- TSATSOULIS, A., SHALET, S.M., ROBERTSON, W.R. MORRIS, I.D., BURGER, H.G. & DE KRETSER, D.M. Plasma inhibin levels in men with chemotherapy-induced severe damage to the seminiferous epithelium, 659
- TUSCHL, R.J. see Pirke, K.M.
- UBUKATA, Y. see Nakamura, Y.
- UITTERLINDEN, P. see Lamberts, S.W.J.
 - ULLOA-AGUIRRE, A., MENDEZ, J.P., GONZALEZ-CASTILLO, A., CARRANZA-LIRA, S., GARZA-FLORES, J. & PEREZ-PALACIOS, G. Changes in the responsiveness of luteinizing hormone secretion

- to infusion of the opioid antagonist nalaxone throughout male sexual maturation, 17
- UMEDA, Y. see Inaba, K.
- URAKAMI, M. see Inaba, K.
- VALCAVI, R., DIEGUEZ, C., PAGE, M.D., ZINI, M., CASOLI, P., PORTIOLI, I. & SCANLON, M.F. Alpha-2-adrenergic pathways release growth hormone via a non-GRF-dependent mechanism in normal human subjects, 309
- VAN DER HEIDE, D. see Looij, B.J.
- VAN KESSEL, H. see Spijkstra, I.J.
- VENTUROLI, S. see Paradisi, R.
- Wass, J.A.H. see Harris, P.E.
- Wass, J.A.H. see Holly, J.M.P.
- WATTS, R.W.E. see Ashby, J.P.
- WHEELER, M. see Treasure, J.L.
- WHEELER, M.H. see Aston, J.P.
- WHITE, A. see Nussey, S.S.
- WHORWOOD, C.B. see Scanlon, M.J.
- WIDE, L. see Rasmussen, C.
- WIKKELSO, C. see Nystrom, E.
- WILSON, S.C., OAKEY, R.E. & SCOTT, J.S. In-vivo and in-vitro endocrine investigation of pure gonadal dysgenesis, 485
- WOODHEAD, J.S. see Aston, J.P.
- Woods, C.A. see Blunt, S.
- Woods, K.L. see O'Malley, B.P.
- Wu, F.C.W. Male contraception: current status and future prospects, 443
- YAMADA, H. see Nakamura, Y.
- YAMADA, Y., KONO, N., HANAFUSA, T., MINEO, I., NAMBA, M., ITOH, H., KIYOKAWA, K., KAWACHI, M., YAMASAKI, T. & TARUI, S. Exaggerated insulin secretory response in patients with insulinomas to midaglizole, a drug with α2-adrenergic blocking activity, 29
- YAMANE, Y. see Inaba, K.
- YAMASAKI, T. see Yamada, Y.
- YLINEN, K. see Ranta, T.
- YOSHIDA, K. see Nakamura, Y.
- YOSHIMURA, Y. see Nakamura, Y.
- YOSHINARI, M. see Sato, K.
- Young, E. see Fletcher, J.
- ZANELLI, J.M. see ASHBY, J.P. ZINI, M. see VALCAVI, R.



Subject Index to Volume 29

Acromegaly

Sandostatin and predictive value of serum somatomedin-C, 411

lowering of GH and prolactin by cabergoline, 467 ACTH-releasing hormone

and pro-opiomelanocortin in thymic tumour in Cushing's syndrome, 649

Addison's disease

production of α-melanocyte-stimulating hormone in the pituitary in, 421

Adrenal adenoma

deoxycorticosterone-producing in hypermineralocorticism, 367

α2-Adrenergic agonist

releases GH by non-GRF-dependent mechanism, 309

α2-Adrenergic blocker

midaglizole in insulinoma, 29

ACTH

inappropriate concentrations in adrenocortical carcinoma, 53

response to oxytocin in insulin-induced hypoglycaemia, 257

Adrenocortical carcinoma

inappropriate ACTH concentrations, 53

Androstanediol glucuronide

and thyroid dysfunction, 529

Anorexia nervosa

weight gain, reproductive function, ultrasonography and endocrine features, 607

Bone density

reversible loss following hypo-oestrogenism with Buserelin, 45

Bradykinin-like immunoreactivity

and pentagastrin-induced carcinoid flush, 141

Bulimia nervosa

gonadotrophins, oestradiol and progesterone during menstrual cycle in, 265

Buserelin

and reversible bone density loss following hypooestrogenism, 45

and menopausal gonadotrophin induce ovulation in PCO disease, 395

effect on pituitary-ovarian response in PCO disease, 403

Cabergoline

lowering of GH and prolactin in dopamineresponsive acromegalics, 467 Calcitonin

effect on GH secretion, 517

Carbimazole

high doses in treatment of thyrotoxicosis, 281

Carcinoid flush

pentagastrin-induced and bradykinin-like immuno-reactivity, 141

Catecholamine

hypothalamic alteration of metabolism in PCO, 317

Cell

kinetics and DNA content in thyroid cancer, 477

muren

GH determination by time series analysis, 35 GH response to oxandrolone in boys, 123

cholinergic muscarinic blockade suppression of GH by pirenzepine, 289

gonadotrophin, GH and prolactin in primary hypothyroidism, 427

neonatal gonadotrophins and sex steroids in infants of men with hypogonadism, 577 insulin secretion and C-peptide, 625

Clominhene

and positive feedback effect of oestradiol, 509

Contraception

male, review, 443

Cortisol

response to oxytocin in insulin-induced hypoglycaemia, 257

C-peptide

and insulin secretion in children, 625

Craniopharyngioma

hCG in cyst fluid and CSF, 503

CRF

in differential diagnosis of Cushing's syndrome, 167

Cushing's syndrome

CRF in differential diagnosis compared with dexamethasone, 167

stressful life events in, 617

hACTH-releasing hormone and pro-opiomelanocortin peptides in thymic tumour, 649

Deoxycorticosterone

and adrenal adenoma and hyperplasia in hypermineralo-corticism, 367

Dexamethasone

in differential diagnosis of Cushing's syndrome, 167

Diabetes mellitus

circadian variation of GH-dependent IGF-binding protein, and insulin, 667

Dopamine agonist

non-ergot, in hyperprolactinaemia, 271

Endocrines

in Swyer's syndrome (pure gonadal dysgenesis), 485

Gene expression

hormonal control of, review, 348

GH

determination in children by time series analysis,

facilitates ovulation by gonadotrophins, 113

response to oxandrolone, 123

response to oxytocin in insulin-induced hypoglycaemia, 257

suppression by cholinergic muscarinic blockade in tall children by pirenzepine, 289

release by alpha-2-adrenergic pathways by non-GRF mechanism, 309

gonadotrophin and prolactin in children with primary hypothyroidism, 427

lowering by cabergoline in dopamine-responsive acromegalics, 467

secretion, effect of calcitonin, 517

Glutathionine S-transferase

restoration of thyrotrophin reduces levels in thyroxine therapy, 249

Gonadal dysgenesis

endocrine investigation in, 485

Gonadotrophin

ovulation induction facilitated by GH, 113

effects of opiate receptor blockade before and after tamoxifen in eugonadal men, 179

during menstrual cycle in bulimia nervosa, 265 and induced ovulation with LHRH analogue in PCO disease, 395

GH and prolactin in children with primary hypothyroidism, 427

in neonatal infants of men with hypogonadism,

LH and PCO with suppression, 633

Graves' disease

thyrotrophin receptor antibodies in, 357 euthyroid, 357

and HLA class II DNA genotypes, 539

Growth deficiency

GH response to oxandrolone, 123 current, therapy, 197

hCG

biological and immunological activity in pregnancy, 495 from cyst fluid and CSF in craniopharyngioma, 503

Head injury

and hypothalamic hypogonadism, 153

Hormones

control of gene expression by, 337

18-Hydroxycortisol

overproduction in familial dexamethasone-suppressible hyperaldosteronism, 297

Hyperaldosteronism

overproduction of 18-hydroxycortisol in familial dexamethasone suppressible, 297

Hypermineralocorticism

and deoxycorticosterone-producing adrenal adenoma, 367

and adrenal hyperplasia, 367

without elevated aldosterone, 367

Hyperparathyroid cells

secretion of PTH, 643

Hyperprolactinaemia

treatment with non-ergot dopamine agonist, 271 Hyperthyroidism

FT4-index in methimazole treatment, 239

Hypoglycaemia

direct radioimmunoassay for proinsulin in, 9 insulin-induced effect of oxytocin on adenophyseal and adrenal cortical responses, 257

Hypogonadism

hypothalamic following head injury, 153 neonatal gonadotrophins and sex hormones in infants of men with, 577

Hypopituitarism

enzyme immunoassay for thyrotrophin in, 387

Hypothalamic hypogonadism

following head injury, 153

Hypothyroidism

L-thyroxine treatment of women with 'subclinical', 63

TSH-dependent elevation of thyroglobulin in, 231

latrogenic damage

to seminiferous epithelium, and inhibin levels, 659 IGF-binding protein

circadian variation of GH-dependent in diabetes

mellitus and insulin, 667

Inhibin

physiology of inhibin and inhibin-related peptides, 77

and chemotherapy-induced damage to seminiferous epithelium, 659

Insulin

secretory response in insulinoma to midaglizole, 29

secretion in children and C-peptide, 625

and circadian variation of GH-dependent IGFbinding protein in diabetes mellitus, 667 Insulin-like GF1

levels in ovarian follicles, 327

Intestinal peptide

vasoactive, and pituitary, 677

LH

feed-back effect of progesterone in post-menopausal women, l

responsiveness to opioid antagonist naloxone in male, 17

responsiveness to naloxone and tamoxifen in male, 179

changes in secretion following orchidectomy, 189 response to Buserelin in PCO disease, 403

surge and clomiphene, 509

PCO and gonadotrophin suppression, 633

α-Melanocyte-stimulating hormone

production in pituitary in Addison's disease, 421 Melatonin

review, 205

Menstrual cycle

in bulimia nervosa, 265

Methimazole

significance of FT4-index in treatment of hyperthyroidism, 239

Midaglizole

and insulin secretory response in insulinoma, 29

Naloxone

and responsiveness of LH in male, 17

effect on LH secretion with tamoxifen in eugonadal men, 179

Anstradio

during menstrual cycle in bulimia nervosa, 265 blockage of positive feedback by clomiphene, 509

Oestrogen receptor blocker

tamoxifen and effects of opiate receptor blockade in eugonadal men, 179

Opiate receptor

effects of blockade on gonadotrophin secretion before and after tamoxifen in eugonadal men, 179

Opioid

antagonist naloxone and responsiveness of LH in male. 17

male, I

and changes in LH secretion, 189

Osteocalcin

stimulated by sodium fluoride, 437

Ovulation

induction by gonadotrophins facilitated by GH, 113

induction in PCO by gonadotrophin with LHRH analogue, 395

and blockage of oestradiol positive feedback by clomiphene, 509

Oxytocin

effect on adenohypophyseal and adrenal cortical responses to insulin-induced hypoglycaemia, 257

PCO syndrome

evidence for hypothalamic alteration of catecholamine metabolism, 317

and insulin-like GF1 in follicular fluid, 327

inducing ovulation with pulsatile menopausal gonadotrophin and GnRH analogue, 395

pituitary-ovarian response during GnRH agonist administration in, 403

familial, 593

LH and gonadotrophin suppression, 633

Pentagastrin

carcinoid flush and bradykinin-like immunoreactivity, 141

Photoperiodism

and melatonin, 205

Pineal gland

and melatonin reviewed, 205

Pirenzepine

cholinergic muscarinic blockade by suppresses GH secretion in tall children, 289

Pituitary function

and vasoactive intestinal peptide, 677

Pregnancy

biological and immunological activity of hCG in,

Progesterone

feedback effect on LH secretion, 1

during menstrual cycle in bulimia nervosa, 265

Proinsulin

direct radioimmunoassay in hypoglycaemia, 9

Prolactin

response to oxytocin in insulin-induced hypoglycaemia, 257

response to non-ergot dopamine agonist in hyperprolactinaemia, 271

gonadotrophin and GH in children with primary hypothyroidism, 427

lowering by cabergoline in dopamine-responsive acromegalics, 467

Pro-opiomelanocortin

and hACTH-releasing hormone in thymic tumour in Cushing's syndrome, 649

Propranolol

with adrenaline releases GH by α₂-adrenergic pathway via non-GRF mechanism, 309

Psychiatric conditions

and melatonin, 218

PTH

assay in normocalcaemic patients with renal stone, 131

secretion by hyperparathyroid cells, 643

Renal stone disease

assay of PTH in normocalcaemic patients, 131

Sandostatin

therapy in acromegaly and predictive value of serum somatomedin-C, 411

Seminiferous epithelium

inhibin and chemotherapy-induced damage to, 659

Sodium fluoride

stimulates osteocalcin, 437

Somatomedin-C

predictive value of serum measurements in treatment of acromegaly with Sandostatin, 411

Stress

in pathogenesis of Cushing's syndrome, 617

Swyer's syndrome

endocrine investigation in, 485

Tamoxifen

opiate receptor blockade and gonadotrophic secretion before and after oestrogen receptor in eugonadal men, 179

Thirst

and osmoregulation of vasopressin secretion, review, 549

Thymus

tumour, hACTH-releasing hormone and proopiomelanocortin peptides in Cushing's syndrome, 649

Thyroglobulin

TSH dependent elevation in primary hypothyroidism, 231

Thyroid

cancer, cell kinetics, DNA content, TSH receptor-adenylate cyclase system, 477

dysfunction and androstanediol glucuronide, 529 abnormalities in gestational trophoblastic neoplasia, 583

Thyrotoxicosis

treatment with high doses of carbimazole, 281

Thyrotrophin

restoration reduces glutathione S-transferase levels in thyroxine therapy, 249

receptor antibodies in euthyroid Graves' disease,

enzyme immunoassay for in hypopituitarism, 387 Thyroxine

treatment of women with 'subclinical' hypothyroidism, 63 restoration of thyrotrophin reduced glutathione S-transferase in therapy with, 249

Trophoblast

thyroid abnormalities in gestational neoplasia, 583

TSH

and elevation of thyroglobulin in primary hypothyroidism, 231

in euthyroid Graves' disease, 357

receptor-adenylate system in thyroid cancer, 477

Vasopressin

platelet receptor, aggregation and binding to platelets, 377

osmoregulation of secretion and thirst, review, 549

Women

feedback effect of progesterone on LH, 1

reversible bone density loss, hypo-oestrogenism and Buserelin, 45

L-thyroxine treatment of 'subclinical' hypothyroidism, 63

gonadotrophins, oestradiol and progesterone during menstrual cycle in bulimia nervosa, 265

with hyperprolactinaemia, treatment with nonergot dopamine agonist, 271

GH facilitates ovulation by gonadotrophins, 113 hypothalamic alteration of catecholamine metabolism in PCO, 317

insulin-like GFI in normal dominant and cohort follicles. PCO and MCO. 327

induction of ovulation by gonadotrophin with GnRH analogue in PCO disease, 395

pituitary-ovarian response to GnRH agonist in PCO syndrome, 403

Swyer's syndrome (pure gonadol dysgenesis) in, 485

biological and immunological activity of hCG in pregnancy, 495

blockage of oestradiol positive feedback by clomiphene, 509

thyroid dysfunction and androstanediol glucuronide, 529

thyroid abnormalities in gestational trophoblastic neoplasia, 583

LH with PCO and gonadotrophin suppression, 633

